# Glycemic Variability of Combination Therapies in T2DM

> **NCT07442006** · PHASE4 · RECRUITING · sponsor: **JW Pharmaceutical** · enrollment: 178 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Empagliflozin/Metformin
- **DRUG:** Anagliptin
- **DRUG:** Metformin
- **DRUG:** Empagliflozin/Linagliptin

## Key facts

- **NCT ID:** NCT07442006
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07442006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07442006, "Glycemic Variability of Combination Therapies in T2DM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07442006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*